LP
CBMG

LMR Partners’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

LMR Partners’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,656
Closed -$156K – 425
2017
Q3 		$156K Sell
14,656
-19,848
-58% -$188K 0.02% 284
2017
Q2 		$302K Buy
+34,504
New +$304K 0.02% 475

Other funds holding CBMG

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

LMR Partners's CBMG Position: Q4 2017 in Review

LMR Partners sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2017, closing a stake of 14,656 shares — an estimated $156K sold.

LMR Partners first reported a position in CBMG in Q2 2017 and held it in 2 quarters. The position peaked at $302K in Q2 2017. 17 funds tracked by Wall St. Rank hold CBMG as of Q4 2017.

  • LMR Partners reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2017 after selling out during the quarter.
  • LMR Partners sold 14,656 Cellular Biomedicine Group, Inc. shares in Q4 2017, an estimated $156K.
  • LMR Partners first reported a position in Cellular Biomedicine Group, Inc. in Q2 2017 and held it in 2 quarters.
  • LMR Partners's Cellular Biomedicine Group, Inc. position peaked at $302K in Q2 2017.
  • 17 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2017.

Based on LMR Partners's 13F filing for Q4 2017, filed 30 Jan 2018.